Screener
Pacific Biosciences of California PACB Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $2.04M-56.6% | $2.01M-53.3% | $2.77M-31.9% | $3M-56.5% | $4.7M-22.6% | ||
| -$44.74M-6.7% | -$8.28M+98.1% | -$40.37M— | -$38M+37.4% | -$41.93M+75.8% | ||
| -$0.140.0% | -$0.03+97.9% | -$0.13+70.5% | -$0.13+40.9% | -$0.14+78.1% | ||
| -$42.29M-2.7% | -$5.14M+91.1% | -$37.44M+73.9% | -$35.4M+33.3% | -$41.18M+75.1% | ||
| -$44.61M+0.5% | -$8.36M+98.1% | -$41.2M+73.1% | -$38.88M+39.3% | -$44.85M+74.5% |
FAQ
- What is Pacific Biosciences of California's revenue?
- Pacific Biosciences of California (PACB) generated $159.3M in revenue over the trailing twelve months, up 2.0% year over year.
- Is Pacific Biosciences of California profitable?
- Pacific Biosciences of California is not currently profitable: it reported a net loss of $131.4M over the trailing twelve months, a -82.5% net margin.
- What are Pacific Biosciences of California's profit margins?
- Gross margin is 36.4% and operating margin is -83.5%, with a -82.5% net margin.
- What is Pacific Biosciences of California's earnings per share?
- Pacific Biosciences of California's diluted EPS over the trailing twelve months is $-0.43.
- Where does Pacific Biosciences of California's income statement data come from?
- Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
